優寧維(301166.SZ):截止到2023年底,公司SKU數已經超過900萬種
格隆匯4月24日丨優寧維(301166.SZ)在投資者互動平台表示,截止到2023年底,公司SKU數已經超過900萬種。公司目前提供的生物試劑產品主要面向科研領域客户,該類客户對於產品的質量、穩定性等要求較高,目前該類生物試劑仍以國外品牌為主。隨着生命科學的蓬勃發展,我國自主品牌的生命科學相關試劑逐漸具有性價比和較高的質量,公司在持續拓展產品管線時,已有部分國產品牌也已納入公司產品體系中,同時通過自主研發等方式,不斷豐富公司產品矩陣,為客户提供更多選擇。 外延方面,公司積極尋找具有業務協同的相關標的,通過投資收購等方式加快公司發展,不斷增強可持續發展能力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.